Celldex Therapeutics
CLDX
53 hedge funds and large institutions have $14.9M invested in Celldex Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 41 closing their positions.
32% more capital invested
Capital invested by funds: $11.3M → $14.9M (+$3.58M)
21.08% more ownership
Funds ownership: 1.99% → 23.07% (+21%)
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
38% less funds holding
Funds holding: 85 → 53 (-32)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
73% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$939K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$651K |
| 3 |
Renaissance Technologies
New York
|
+$540K |
| 4 |
D.E. Shaw & Co
New York
|
+$530K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$372K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
-$1.36M |
| 2 |
Two Sigma Investments
New York
|
-$345K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$250K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$243K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$156K |
CLDX Hedge Fund Activity: Q1 2019 in Review
53 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2019, worth a combined $14.9M — up 32% from $11.3M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of CLDX and 11 opened new positions — a net loss of 30 holders — while 17 trimmed existing stakes and 20 added.
The largest buyer was BlackRock, adding an estimated $939K. The largest seller was Cresset Asset Management, exiting entirely with an estimated $1.36M sold.
- 53 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2019, down from 85 in Q4 2018.
- Funds reported $14.9M of Celldex Therapeutics stock for Q1 2019, up 32% quarter-over-quarter.
- 11 funds opened new Celldex Therapeutics positions in Q1 2019 and 41 closed out, a net change of -30 holders.
- The largest Celldex Therapeutics buyer in Q1 2019 was BlackRock, an estimated $939K added.
- The largest Celldex Therapeutics seller in Q1 2019 was Cresset Asset Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q1 2019.